DK3779447T3 - Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer - Google Patents

Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer Download PDF

Info

Publication number
DK3779447T3
DK3779447T3 DK20195759.4T DK20195759T DK3779447T3 DK 3779447 T3 DK3779447 T3 DK 3779447T3 DK 20195759 T DK20195759 T DK 20195759T DK 3779447 T3 DK3779447 T3 DK 3779447T3
Authority
DK
Denmark
Prior art keywords
tumoral
cancer
activating
cell response
patient affected
Prior art date
Application number
DK20195759.4T
Other languages
English (en)
Inventor
Kim In-San
Ana Hennino
Philippe Bertolino
Original Assignee
Inst Nat Sante Rech Med
Univ Claude Bernard Lyon
Centre Nat Rech Scient
Centre Leon Berard
Kist Korea Institute Of Science And Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Claude Bernard Lyon, Centre Nat Rech Scient, Centre Leon Berard, Kist Korea Institute Of Science And Tech filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3779447T3 publication Critical patent/DK3779447T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20195759.4T 2016-03-15 2017-03-15 Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer DK3779447T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305276 2016-03-15
EP17710554.1A EP3430404B1 (en) 2016-03-15 2017-03-15 Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease

Publications (1)

Publication Number Publication Date
DK3779447T3 true DK3779447T3 (da) 2023-04-24

Family

ID=55588194

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20195759.4T DK3779447T3 (da) 2016-03-15 2017-03-15 Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer
DK17710554.1T DK3430404T3 (da) 2016-03-15 2017-03-15 Tidlig og non-invasiv fremgangsmåde til vurdering af et individs risiko for at få duktalt adenokarcinom i bugspytkirtlen og fremgangsmåder til behandling af en sådan sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17710554.1T DK3430404T3 (da) 2016-03-15 2017-03-15 Tidlig og non-invasiv fremgangsmåde til vurdering af et individs risiko for at få duktalt adenokarcinom i bugspytkirtlen og fremgangsmåder til behandling af en sådan sygdom

Country Status (10)

Country Link
US (2) US11740243B2 (da)
EP (2) EP3779447B1 (da)
JP (3) JP6903680B2 (da)
KR (2) KR102402444B1 (da)
DK (2) DK3779447T3 (da)
ES (2) ES2911038T3 (da)
FI (1) FI3779447T3 (da)
HR (2) HRP20220335T1 (da)
PL (2) PL3779447T3 (da)
WO (1) WO2017158043A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3779447B1 (en) * 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
US20210340240A1 (en) * 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
KR102169346B1 (ko) * 2019-03-27 2020-10-23 덕성여자대학교 산학협력단 이종이식 동물 모델의 제조방법 및 이종이식 성공 여부 판별 방법
IL310437A (en) 2021-07-29 2024-03-01 Inst Nat Sante Rech Med Humanized anti-human βig-h3 protein and uses thereof
WO2025068157A1 (en) * 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025224297A1 (en) * 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
AU2002348583B2 (en) * 2002-04-19 2006-12-07 Regen Biotech, Inc. The method for measuring the amount of betaig-h3 protein and diagnostic kit using the same
KR20060056445A (ko) 2004-11-19 2006-05-24 주식회사 리젠 바이오텍 인간 βｉｇ－ｈ３에 대한 단클론 항체
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
EP2463657A1 (en) 2010-12-13 2012-06-13 Université de Liège Biomarkers, uses of biomarkers and a method of identifying biomarkers
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US9845471B2 (en) * 2013-01-15 2017-12-19 Fred Hutchinson Cancer Research Center Compositions and methods for treating pancreatic cancer
KR101515700B1 (ko) 2013-05-15 2015-04-27 경북대학교 산학협력단 Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법
EP3598980B1 (en) 2014-06-26 2026-01-28 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
EP3779447B1 (en) * 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
KR102082344B1 (ko) * 2018-06-21 2020-02-27 조성은 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 용도

Also Published As

Publication number Publication date
EP3779447A1 (en) 2021-02-17
HRP20220335T1 (hr) 2022-05-13
ES2911038T3 (es) 2022-05-17
US12140594B2 (en) 2024-11-12
KR20180120716A (ko) 2018-11-06
PL3430404T3 (pl) 2022-05-02
EP3430404A1 (en) 2019-01-23
JP6903680B2 (ja) 2021-07-14
EP3779447B1 (en) 2023-02-08
JP2021119146A (ja) 2021-08-12
US20190086417A1 (en) 2019-03-21
US11740243B2 (en) 2023-08-29
JP2023052360A (ja) 2023-04-11
HRP20230391T1 (hr) 2023-07-07
WO2017158043A1 (en) 2017-09-21
DK3430404T3 (da) 2022-03-21
JP7569741B2 (ja) 2024-10-18
KR20210059020A (ko) 2021-05-24
FI3779447T3 (fi) 2023-04-21
EP3430404B1 (en) 2022-01-05
KR102402444B1 (ko) 2022-05-27
PL3779447T3 (pl) 2023-06-26
ES2944259T3 (es) 2023-06-20
JP2019512695A (ja) 2019-05-16
KR102408161B1 (ko) 2022-06-13
US20240159759A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
DK3294762T3 (da) Ekspressionskonstruktioner og fremgangsmåder til genmanipulering af methylotrof gær
IL254734B1 (en) Modified t cells and methods of making and using the same
EP3448485A4 (en) PATIENT INTERFACE
EP3496074A4 (en) MEDICAL SIMULATOR
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
DK3389564T3 (da) Hjerteklapprotese
EP3443506C0 (fr) Neurone artificiel
EP3522966A4 (en) PATIENT INTERFACES
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
LT3097119T (lt) Žmogaus antikūnai prieš pd-1
DK3777772T3 (da) Protese til hjerteklap
DK3351239T3 (da) Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf
IL262776A (en) Humanized anti-il-1r3 antibodies
DK3151875T3 (da) Humane lever-scaffolds
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3255980T3 (da) Bivenlig kunstig bikage
EP3487471A4 (en) ARTIFICIAL TEAT PROTECTION AGAINST BITES
DK3042559T3 (da) Anordning til bekæmpelse af varroa-miden i biyngel
IL272924B1 (en) Methods for making and using endoxifen
IL256381A (en) Cryoprecipitate compositions and methods of preparation thereof
DK3188721T3 (da) Humane terapeutika
DK3779447T3 (da) Fremgangsmåde til at aktivere den anti-tumorale CD8+T-celle-respons hos en patient påvirket af en cancer
EP3500208C0 (de) Dental-prothetiksystem
IL260347A (en) Therapeutic anti-cd9 antibody